Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Structural basis of subtype-selective competitive antagonism for GluN2C/2D-containing NMDA receptors.

Wang JX, Irvine MW, Burnell ES, Sapkota K, Thatcher RJ, Li M, Simorowski N, Volianskis A, Collingridge GL, Monaghan DT, Jane DE, Furukawa H.

Nat Commun. 2020 Jan 22;11(1):423. doi: 10.1038/s41467-020-14321-0.

2.

Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid.

Irvine MW, Fang G, Sapkota K, Burnell ES, Volianskis A, Costa BM, Culley G, Collingridge GL, Monaghan DT, Jane DE.

Eur J Med Chem. 2019 Feb 15;164:471-498. doi: 10.1016/j.ejmech.2018.12.054. Epub 2018 Dec 28. Review.

3.

The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators.

Sapkota K, Dore K, Tang K, Irvine M, Fang G, Burnell ES, Malinow R, Jane DE, Monaghan DT.

Biochem Pharmacol. 2019 Jan;159:140-153. doi: 10.1016/j.bcp.2018.11.018. Epub 2018 Nov 29.

4.

Assembly and Trafficking of Homomeric and Heteromeric Kainate Receptors with Impaired Ligand Binding Sites.

Scholefield CL, Atlason PT, Jane DE, Molnár E.

Neurochem Res. 2019 Mar;44(3):585-599. doi: 10.1007/s11064-018-2654-0. Epub 2018 Oct 9.

5.

The 1980s: D-AP5, LTP and a Decade of NMDA Receptor Discoveries.

Lodge D, Watkins JC, Bortolotto ZA, Jane DE, Volianskis A.

Neurochem Res. 2019 Mar;44(3):516-530. doi: 10.1007/s11064-018-2640-6. Epub 2018 Oct 4.

6.

Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity.

Ingram R, Kang H, Lightman S, Jane DE, Bortolotto ZA, Collingridge GL, Lodge D, Volianskis A.

Neuropharmacology. 2018 Nov;142:30-40. doi: 10.1016/j.neuropharm.2018.06.008. Epub 2018 Jun 6. Review.

PMID:
29885421
7.

Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.

Burnell ES, Irvine M, Fang G, Sapkota K, Jane DE, Monaghan DT.

J Med Chem. 2019 Jan 10;62(1):3-23. doi: 10.1021/acs.jmedchem.7b01640. Epub 2018 Mar 5. Review.

8.

A single-channel mechanism for pharmacological potentiation of GluN1/GluN2A NMDA receptors.

Chopra DA, Sapkota K, Irvine MW, Fang G, Jane DE, Monaghan DT, Dravid SM.

Sci Rep. 2017 Jul 31;7(1):6933. doi: 10.1038/s41598-017-07292-8.

9.

Mechanism and properties of positive allosteric modulation of N-methyl-d-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives.

Sapkota K, Irvine MW, Fang G, Burnell ES, Bannister N, Volianskis A, Culley GR, Dravid SM, Collingridge GL, Jane DE, Monaghan DT.

Neuropharmacology. 2017 Oct;125:64-79. doi: 10.1016/j.neuropharm.2017.07.007. Epub 2017 Jul 11.

10.

Multiple roles of GluN2B-containing NMDA receptors in synaptic plasticity in juvenile hippocampus.

France G, Fernández-Fernández D, Burnell ES, Irvine MW, Monaghan DT, Jane DE, Bortolotto ZA, Collingridge GL, Volianskis A.

Neuropharmacology. 2017 Jan;112(Pt A):76-83. doi: 10.1016/j.neuropharm.2016.08.010. Epub 2016 Aug 12.

11.

Synthesis of a Series of Novel 3,9-Disubstituted Phenanthrenes as Analogues of Known NMDA Receptor Allosteric Modulators.

Irvine MW, Fang G, Eaves R, Mayo-Martin MB, Burnell ES, Costa BM, Culley GR, Volianskis A, Collingridge GL, Monaghan DT, Jane DE.

Synthesis (Stuttg). 2015 Jun 1;47(11):1593-1610. doi: 10.1055/s-0034-1380114.

12.

An interchangeable role for kainate and metabotropic glutamate receptors in the induction of rat hippocampal mossy fiber long-term potentiation in vivo.

Wallis JL, Irvine MW, Jane DE, Lodge D, Collingridge GL, Bortolotto ZA.

Hippocampus. 2015 Nov;25(11):1407-17. doi: 10.1002/hipo.22460. Epub 2015 Apr 25.

13.

Long-term potentiation and the role of N-methyl-D-aspartate receptors.

Volianskis A, France G, Jensen MS, Bortolotto ZA, Jane DE, Collingridge GL.

Brain Res. 2015 Sep 24;1621:5-16. doi: 10.1016/j.brainres.2015.01.016. Epub 2015 Jan 22. Review.

14.

Design and nuclear magnetic resonance (NMR) structure determination of the second extracellular immunoglobulin tyrosine kinase A (TrkAIg2) domain construct for binding site elucidation in drug discovery.

Shoemark DK, Williams C, Fahey MS, Watson JJ, Tyler SJ, Scoltock SJ, Ellis RZ, Wickenden E, Burton AJ, Hemmings JL, Bailey CD, Dawbarn D, Jane DE, Willis CL, Sessions RB, Allen SJ, Crump MP.

J Med Chem. 2015 Jan 22;58(2):767-77. doi: 10.1021/jm501307e. Epub 2014 Dec 22.

15.

NMDA receptor-dependent long-term potentiation comprises a family of temporally overlapping forms of synaptic plasticity that are induced by different patterns of stimulation.

Park P, Volianskis A, Sanderson TM, Bortolotto ZA, Jane DE, Zhuo M, Kaang BK, Collingridge GL.

Philos Trans R Soc Lond B Biol Sci. 2013 Dec 2;369(1633):20130131. doi: 10.1098/rstb.2013.0131. Print 2014 Jan 5. Review.

16.

Antagonists reversibly reverse chemical LTD induced by group I, group II and group III metabotropic glutamate receptors.

Lodge D, Tidball P, Mercier MS, Lucas SJ, Hanna L, Ceolin L, Kritikos M, Fitzjohn SM, Sherwood JL, Bannister N, Volianskis A, Jane DE, Bortolotto ZA, Collingridge GL.

Neuropharmacology. 2013 Nov;74:135-46. doi: 10.1016/j.neuropharm.2013.03.011. Epub 2013 Mar 26.

PMID:
23542080
17.

Different NMDA receptor subtypes mediate induction of long-term potentiation and two forms of short-term potentiation at CA1 synapses in rat hippocampus in vitro.

Volianskis A, Bannister N, Collett VJ, Irvine MW, Monaghan DT, Fitzjohn SM, Jensen MS, Jane DE, Collingridge GL.

J Physiol. 2013 Feb 15;591(4):955-72. doi: 10.1113/jphysiol.2012.247296. Epub 2012 Dec 10.

18.

Characterisation of an mGlu8 receptor-selective agonist and antagonist in the lateral and medial perforant path inputs to the dentate gyrus.

Mercier MS, Lodge D, Fang G, Nicolas CS, Collett VJ, Jane DE, Collingridge GL, Bortolotto ZA.

Neuropharmacology. 2013 Apr;67:294-303. doi: 10.1016/j.neuropharm.2012.11.020. Epub 2012 Dec 5.

PMID:
23220400
19.

The NMDA receptor as a target for cognitive enhancement.

Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, Tidball P, Fang G, Irvine MW, Costa BM, Monaghan DT, Bortolotto ZA, Molnár E, Lodge D, Jane DE.

Neuropharmacology. 2013 Jan;64:13-26. doi: 10.1016/j.neuropharm.2012.06.051. Epub 2012 Jul 11. Review.

20.

Differences in kainate receptor involvement in hippocampal mossy fibre long-term potentiation depending on slice orientation.

Sherwood JL, Amici M, Dargan SL, Culley GR, Fitzjohn SM, Jane DE, Collingridge GL, Lodge D, Bortolotto ZA.

Neurochem Int. 2012 Sep;61(4):482-9. doi: 10.1016/j.neuint.2012.04.021. Epub 2012 Apr 27.

PMID:
22564530
21.

Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.

Monaghan DT, Irvine MW, Costa BM, Fang G, Jane DE.

Neurochem Int. 2012 Sep;61(4):581-92. doi: 10.1016/j.neuint.2012.01.004. Epub 2012 Jan 17. Review.

22.

Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors.

Irvine MW, Costa BM, Volianskis A, Fang G, Ceolin L, Collingridge GL, Monaghan DT, Jane DE.

Neurochem Int. 2012 Sep;61(4):593-600. doi: 10.1016/j.neuint.2011.12.020. Epub 2012 Jan 13.

23.

Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.

Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Laube B, Jane DE, Monaghan DT.

Neuropharmacology. 2012 Mar;62(4):1730-6. doi: 10.1016/j.neuropharm.2011.11.019. Epub 2011 Dec 6.

24.

Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.

Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB, Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnár E, Monaghan DT, Jane DE.

J Med Chem. 2012 Jan 12;55(1):327-41. doi: 10.1021/jm201230z. Epub 2011 Dec 14.

25.

Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo.

Jullienne A, Montagne A, Orset C, Lesept F, Jane DE, Monaghan DT, Maubert E, Vivien D, Ali C.

Mol Neurodegener. 2011 Oct 5;6:68. doi: 10.1186/1750-1326-6-68.

26.

Pre- and post-synaptic functions of kainate receptors at glutamate and GABA synapses in the rat entorhinal cortex.

Chamberlain SE, Jane DE, Jones RS.

Hippocampus. 2012 Mar;22(3):555-76. doi: 10.1002/hipo.20921. Epub 2011 Mar 1.

PMID:
21365713
27.

Pharmacology of NMDA Receptors.

Monaghan DT, Jane DE.

In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 12.

28.

A novel family of negative and positive allosteric modulators of NMDA receptors.

Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, Jane DE, Monaghan DT.

J Pharmacol Exp Ther. 2010 Dec;335(3):614-21. doi: 10.1124/jpet.110.174144. Epub 2010 Sep 21.

29.

Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310.

Atlason PT, Scholefield CL, Eaves RJ, Mayo-Martin MB, Jane DE, Molnár E.

Mol Pharmacol. 2010 Dec;78(6):1036-45. doi: 10.1124/mol.110.067934. Epub 2010 Sep 13.

30.

Metabotropic glutamate receptor mGlu2 is resistant to homologous agonist-induced desensitization but undergoes protein kinase C-mediated heterologous desensitization.

Lennon SM, Rivero G, Matharu A, Howson PA, Jane DE, Roberts PJ, Kelly E.

Eur J Pharmacol. 2010 Dec 15;649(1-3):29-37. doi: 10.1016/j.ejphar.2010.08.038. Epub 2010 Sep 15.

PMID:
20826132
31.

Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones.

Suárez F, Zhao Q, Monaghan DT, Jane DE, Jones S, Gibb AJ.

Eur J Neurosci. 2010 Aug;32(3):359-67. doi: 10.1111/j.1460-9568.2010.07298.x. Epub 2010 Jul 6.

32.

Allosteric block of KCa2 channels by apamin.

Lamy C, Goodchild SJ, Weatherall KL, Jane DE, Liégeois JF, Seutin V, Marrion NV.

J Biol Chem. 2010 Aug 27;285(35):27067-77. doi: 10.1074/jbc.M110.110072. Epub 2010 Jun 18.

33.

Small conductance calcium-activated potassium channels: from structure to function.

Weatherall KL, Goodchild SJ, Jane DE, Marrion NV.

Prog Neurobiol. 2010 Jul;91(3):242-55. doi: 10.1016/j.pneurobio.2010.03.002. Epub 2010 Mar 30. Review.

PMID:
20359520
34.

Ca2+-calmodulin increases RyR2 open probability yet reduces ryanoid association with RyR2.

Sigalas C, Mayo-Martin MB, Jane DE, Sitsapesan R.

Biophys J. 2009 Oct 7;97(7):1907-16. doi: 10.1016/j.bpj.2009.07.027.

35.

N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse.

Costa BM, Feng B, Tsintsadze TS, Morley RM, Irvine MW, Tsintsadze V, Lozovaya NA, Jane DE, Monaghan DT.

J Pharmacol Exp Ther. 2009 Nov;331(2):618-26. doi: 10.1124/jpet.109.156752. Epub 2009 Aug 14.

36.

GLUK1 receptor antagonists and hippocampal mossy fiber function.

Nisticò R, Dargan S, Fitzjohn SM, Lodge D, Jane DE, Collingridge GL, Bortolotto ZA.

Int Rev Neurobiol. 2009;85:13-27. doi: 10.1016/S0074-7742(09)85002-2. Review.

PMID:
19607958
37.

Mechanisms of antagonism of the GluR2 AMPA receptor: structure and dynamics of the complex of two willardiine antagonists with the glutamate binding domain.

Ahmed AH, Thompson MD, Fenwick MK, Romero B, Loh AP, Jane DE, Sondermann H, Oswald RE.

Biochemistry. 2009 May 12;48(18):3894-903. doi: 10.1021/bi900107m.

38.

The role of GLU K5-containing kainate receptors in entorhinal cortex gamma frequency oscillations.

Stanger HL, Alford R, Jane DE, Cunningham MO.

Neural Plast. 2008;2008:401645. doi: 10.1155/2008/401645. Epub 2008 Nov 17.

39.

Extrasynaptic NR2D-containing NMDARs are recruited to the synapse during LTP of NMDAR-EPSCs.

Harney SC, Jane DE, Anwyl R.

J Neurosci. 2008 Nov 5;28(45):11685-94. doi: 10.1523/JNEUROSCI.3035-08.2008.

40.

Mechanism of partial agonism at the GluR2 AMPA receptor: Measurements of lobe orientation in solution.

Maltsev AS, Ahmed AH, Fenwick MK, Jane DE, Oswald RE.

Biochemistry. 2008 Oct 7;47(40):10600-10. doi: 10.1021/bi800843c. Epub 2008 Sep 17.

41.

Kainate receptors: pharmacology, function and therapeutic potential.

Jane DE, Lodge D, Collingridge GL.

Neuropharmacology. 2009 Jan;56(1):90-113. doi: 10.1016/j.neuropharm.2008.08.023. Epub 2008 Aug 28. Review.

PMID:
18793656
42.

ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function.

Dargan SL, Clarke VR, Alushin GM, Sherwood JL, Nisticò R, Bortolotto ZA, Ogden AM, Bleakman D, Doherty AJ, Lodge D, Mayer ML, Fitzjohn SM, Jane DE, Collingridge GL.

Neuropharmacology. 2009 Jan;56(1):121-30. doi: 10.1016/j.neuropharm.2008.08.016. Epub 2008 Aug 22.

43.

Antagonism of recombinant and native GluK3-containing kainate receptors.

Perrais D, Pinheiro PS, Jane DE, Mulle C.

Neuropharmacology. 2009 Jan;56(1):131-40. doi: 10.1016/j.neuropharm.2008.08.002. Epub 2008 Aug 12.

PMID:
18761361
44.

NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones.

Brothwell SL, Barber JL, Monaghan DT, Jane DE, Gibb AJ, Jones S.

J Physiol. 2008 Feb 1;586(3):739-50. Epub 2007 Nov 22.

45.

Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.

Dolman NP, More JC, Alt A, Knauss JL, Pentikäinen OT, Glasser CR, Bleakman D, Mayer ML, Collingridge GL, Jane DE.

J Med Chem. 2007 Apr 5;50(7):1558-70. Epub 2007 Mar 10.

PMID:
17348638
46.

Dynamics of the S1S2 glutamate binding domain of GluR2 measured using 19F NMR spectroscopy.

Ahmed AH, Loh AP, Jane DE, Oswald RE.

J Biol Chem. 2007 Apr 27;282(17):12773-84. Epub 2007 Mar 2.

47.

Inhibition of kainate receptors reduces the frequency of hippocampal theta oscillations.

Huxter JR, Zinyuk LE, Roloff Ev, Clarke VR, Dolman NP, More JC, Jane DE, Collingridge GL, Muller RU.

J Neurosci. 2007 Feb 28;27(9):2212-23.

48.

Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.

Dolman NP, More JC, Alt A, Knauss JL, Troop HM, Bleakman D, Collingridge GL, Jane DE.

J Med Chem. 2006 Apr 20;49(8):2579-92.

PMID:
16610801
49.

The different effects on recognition memory of perirhinal kainate and NMDA glutamate receptor antagonism: implications for underlying plasticity mechanisms.

Barker GR, Warburton EC, Koder T, Dolman NP, More JC, Aggleton JP, Bashir ZI, Auberson YP, Jane DE, Brown MW.

J Neurosci. 2006 Mar 29;26(13):3561-6.

50.

Supplemental Content

Support Center